Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include CAR-T cell therapy research, Prostate Cancer Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, and Melanoma and MAPK Pathways.
Recurrence of Hepatocellular Carcinoma After Complete Radiologic Response to Trans-Arterial Embolization: A Retrospective Study on Patterns, Treatments, and Prognoses
Genomic Predictors of Recurrence Patterns After Complete Resection of Colorectal Liver Metastases and Adjuvant Hepatic Artery Infusion Chemotherapy
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma
Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma – An exploratory analysis
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery Chemotherapy
A phase II study to evaluate the need for > two doses of nivolumab + ipilimumab combination (combo) immunotherapy.
Preoperative nomogram predicting 12-year probability of metastatic renal cancer – evaluation in a contemporary cohort
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile
Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study
Regional differences in gallbladder cancer pathogenesis: Insights from a multi‐institutional comparison of tumor mutations
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era
A phase II study of radioimmunotherapy with intraventricular <sup>131</sup>I‐3F8 for medulloblastoma
18F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer
Prospective Clinical Trial of <sup>18</sup>F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers
Comparison of <sup>18</sup>F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma
Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype
Retrospective Analysis of <sup>18</sup>F-FDG PET/CT for Staging Asymptomatic Breast Cancer Patients Younger Than 40 Years
Preoperative 3-T Diffusion-Weighted MRI for the Qualitative and Quantitative Assessment of Extracapsular Extension in Patients With Intermediate- or High-Risk Prostate Cancer